Pfizer (NYSE:PFE) Trading 1.6% Higher – What’s Next?

Pfizer Inc. (NYSE:PFE) shares shot up 1.6% during mid-day trading on Tuesday . The company traded as high as $27.40 and last traded at $27.2950. 34,599,379 shares were traded during trading, a decline of 18% from the average daily volume of 42,104,363 shares. The stock had previously closed at $26.87.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Lyme vaccine filing advances in Europe: The European Medicines Agency validated Pfizer and Valneva’s marketing application for their Lyme disease vaccine candidate, confirming that the submission is ready for full regulatory review. The filing follows late-stage results showing 73% efficacy and encouraging safety data, improving the prospects for a future product launch and potential royalty income. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Pipeline diversification continues: Pfizer completed a Phase 1 study of experimental obesity drug PF-08653944. The program remains at an early stage, so it is not an immediate earnings driver, but progress could help investors looking for growth areas beyond Pfizer’s mature COVID-19 portfolio. Pfizer Advances Early Obesity Drug PF-08653944
• Positive Sentiment: Healthcare-sector support: The broader healthcare sector was higher during Tuesday’s session, providing a favorable trading backdrop for Pfizer and other defensive pharmaceutical stocks. Healthcare Stocks Rise Tuesday Afternoon
• Neutral Sentiment: Valuation and income appeal: Commentary continues to characterize Pfizer as inexpensive and supported by a sizable dividend, with pharmaceuticals offering relatively defensive demand. These benefits may attract income-oriented investors, although they depend on stable cash flow and successful replacement of aging products. Warren Buffett and Greg Abel Keep Overlooking This Stock
• Negative Sentiment: Patent-cliff risk remains: Analysts note that Pfizer’s low valuation reflects looming patent expirations and the resulting threat to revenue and earnings. Investors will therefore need to weigh the Lyme vaccine and obesity programs against the timing and scale of replacement products. Pfizer Still Cheap Valuation Meets a Looming Patent Cliff

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PFE. JPMorgan Chase & Co. cut their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. Guggenheim decreased their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Stock Performance

The business’s fifty day moving average price is $25.15 and its two-hundred day moving average price is $26.20. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock has a market capitalization of $155.57 billion, a P/E ratio of 35.91 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the firm earned $0.78 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. Pfizer’s payout ratio is currently 226.32%.

Institutional Trading of Pfizer

Institutional investors have recently bought and sold shares of the stock. Handelsbanken Fonder AB lifted its holdings in Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after buying an additional 232,528 shares in the last quarter. Vanguard Group Inc. grew its stake in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares in the last quarter. North Dakota State Investment Board purchased a new position in shares of Pfizer during the fourth quarter worth approximately $5,348,000. PFA Pension Forsikringsaktieselskab bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $76,833,000. Finally, Park National Corp OH increased its holdings in Pfizer by 332.1% during the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 186,053 shares during the period. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.